What’s happening at Innocore?

Experience the energy of Swiss Biotech Day 2026, and join us as we connect, inspire, and shape the future of biotech in Basel this May.

Innocore strengthens strategic U.S. presence through new long-acting injectable development collaboration.

We are proud to announce the appointment of Hans de Backer as Chief Executive Officer. Hans joins the company with a proven track record as a strategy‑driven business leader, recognized for delivering sustainable growth, shepherding complex organizations, and building energized, high‑performance teams.

Join Rob Steendam during his presentation or meet Vincent de Boer and Martin Bakker to discuss our proprietary SynBiosys platform for sustained release of peptides and biologics

We’re thrilled to announce that InnoCore has been awarded a Just Transition Fund (JTF) to develop a peptide microsphere long-acting injectable. This milestone underscores the innovation and impact of our sustained-release platform in metabolic health. Stay tuned as we accelerate toward transformative solutions in peptide delivery.

InnoCore Pharmaceuticals today initiated a new formulation development program focused on a specific small molecule drug substance, reinforcing its long-standing commitment to supporting its customers across a range of molecules.

InnoCore attended and presented at the PODD: Partnership Opportunities in Drug Delivery Conference, taking place between 27–28 October 2025 in Boston, MA.

InnoCore Pharmaceuticals today announced a project extension with an existing European biotech partner focused on developing a long-acting injectable protein formulation using its proprietary SynBiosys® technology.

Innocore today announced a new formulation development contract with a returning Top 10 global pharmaceutical company. The new agreement builds on the success of earlier collaborations and further strengthens the long-standing relationship between the two companies.